CASH Capital

CASH Capital is a Beijing-based venture firm with affiliation to the Chinese Academy of Sciences, the country’s premier scientific research institution, and that linkage shapes everything about the firm’s strategy. Investment activity centers on biotech, life sciences tools, and deep tech, with a clear emphasis on commercializing hard science emerging from Chinese academic and research institutions. The firm understands the long arc of early scientific risk, IP translation, and the maturation of research-stage projects into operating companies, in a way that many financial investors lack. Limited public information is available about specific named partners or a complete portfolio list in English-language sources, but the institutional anchor is the firm’s defining feature.

The firm writes checks of approximately one to five million dollars and concentrates on Series A and Series B rounds rather than the earliest formation work or large growth checks. Geographic focus is China, with particular density around opportunities that come out of Chinese Academy of Sciences institutes and affiliated research networks. Founders without a tie to that ecosystem are less likely to find a natural entry point.

For scientific founders working in Chinese hard science, biotech, or life sciences tools, CASH Capital is one of the more relevant venture conversations available. Expect a partner that reads the science deeply, engages on technical milestones rather than only commercial metrics, and operates on a longer time horizon than consumer-oriented investors. Pure software, digital health, or commercial-stage companies far from the lab will likely be outside the fit. The right match is a research-driven company that benefits from an investor who can navigate both the science and the institutional context behind it.